Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 10/20 | 0.50 |
| ▸ | HTR1A | P08908 | 9/20 | 0.50 |
| ▸ | DRD2 | P14416 | 9/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400812 | 0.91 | HTR2A (0.47) | HTR2AHTR1ADRD2HTR7DRD4 | |
| SCHEMBL6397678 | 0.89 | HTR2A (0.48) | HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL5738711 | 0.85 | MEN1 (0.39) | HTR1A | |
| SCHEMBL6401061 | 0.84 | HTR2A (0.46) | HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL5738767 | 0.82 | HTR2A (0.51) | HTR2AHTR1ADRD2 | |
| SCHEMBL6400851 | 0.82 | — | — | |
| SCHEMBL6398289 | 0.81 | DRD2 (0.52) | HTR2AHTR1ADRD2HTR7DRD4 | |
| SCHEMBL6399207 | 0.81 | HTR2A (0.50) | HTR2AHTR1ADRD2HTR7DRD4 | |
| SCHEMBL6401523 | 0.81 | HTR2A (0.43) | HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL6398303 | 0.80 | HTR2A (0.49) | HTR2AHTR1ADRD2HTR7DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | HTR2A 195/4885HTR1A 61/4885DRD2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.